Search for other works by this author on: ...

1Fred Hutchinson Cancer Center, Seattle, WA.

Search for other works by this author on: ...

Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metastatic disease which often follows long periods of clinical dormancy. Understanding the ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Jaleh Fallah, U.S. Center for Drug Evaluation and Research, Office of New ...

Bristol Myers Squibb (BMS) faces a $6.7 billion lawsuit alleging that the company purposely delayed approval of Celgene-developed drugs to avoid paying Celgene shareholders owning contingent value ...

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Medicine, Weill Cornell Medical College, New York, New York. *Corresponding Author: Claire F.

1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...

Today, Merck announced that it will acquire LaNova Medicines’ PD-1/VEGF bispecific antibody, LM-299, for $588 million upfront plus financial awards that could reach $2.7 billion if certain development ...

Major Finding: Antitumor T cells are recruited to intracranial metastases through ICAM-1 + peritumoral venous vessels (PVV). Concept: PVVs mediate T-cell recruitment and motility, which can be ...